Dormant
CME · CME Group Inc.
Last analysed ·
Current thesis
CME Group's product-launch story requires its September–October factor, hockey and compute contracts to begin trading on schedule. Missed launch dates or a weekly close below $272 would invalidate the near-term case.
Kill line
A weekly close below $272 breaches the research threshold published on 2026-08-30. Failure of factor, NHL or compute futures to begin trading on 2026-09-21, 2026-09-28 or 2026-10-05, respectively, also breaks the execution thesis.
Pick status
Open commitment catalyst in 1dscored if the kill line above fires How this is scored →Latest analysis and events for CME —
As of 13 September 2026, the latest FrontierPicks analysis for CME Group Inc. (CME): CME Group's product-launch story requires its September–October factor, hockey and compute contracts to begin trading on schedule. Missed launch dates or a weekly close below $272 would invalidate the near-term case.
Kill line: A weekly close below $272 breaches the research threshold published on 2026-08-30. Failure of factor, NHL or compute futures to begin trading on 2026-09-21, 2026-09-28 or 2026-10-05, respectively, also breaks the execution thesis.
Next dated event on file: — catalyst in 1d.
Current Thesis
CME Group's product-launch thesis depends on converting its September–October schedule into traded contracts before a weekly close below $272 breaks the published price condition. The near-term case requires factor, hockey and compute contracts to begin trading on their announced dates; listing announcements alone do not establish customer adoption.
The operating evidence has advanced: CME reported August 2026 average daily volume (ADV) of 29.7 million contracts, up 6% year over year, on 2026-09-02. That supports continued activity in the existing franchise but cannot demonstrate demand for contracts scheduled to launch afterward. CME August volume release
As an inference, the narrative is maturing — the announcements dated 2026-08-11 and 2026-08-27 now face listing deadlines on 2026-09-28 and 2026-09-21. Recorded trading and subsequent open interest would establish progress beyond announcements; missed launch dates would invalidate that execution case. NHL announcement, factor announcement
Bullish and bearish views on CME Group Inc.
The model's bull view on CME Group Inc. (CME), in brief: Existing markets support the expansion. CME's 2026-09-02 release reported August interest-rate ADV of 16.7 million contracts, up 3% year over year, and metals ADV growth of 48%. These are measured activity gains in established products. CME volume release Factor contracts… The bear view: Sports expansion has a qualification. CME's 2026-09-07 notice scheduled an end to additional sports and cultural event-swap expiries effective 2026-09-11, pending regulatory review. The notice concerns event swaps; it does not establish cancellation of the separately announced… Both cases follow in full.
Bull Case
- Existing markets support the expansion. CME's 2026-09-02 release reported August interest-rate ADV of 16.7 million contracts, up 3% year over year, and metals ADV growth of 48%. These are measured activity gains in established products. CME volume release
- Factor contracts connect existing products. The 2026-08-27 announcement makes the planned 2026-09-21 factor futures eligible for margin offsets against other cleared equity products. This provides a concrete connection to CME's existing market; it does not establish future volume. CME factor announcement
- Analyst support remains observable. TD Cowen maintained its $292 price target on 2026-09-03. The action supports the existence of a constructive analyst view, without constituting an estimate increase or evidence of new investor demand. Benzinga analyst history
Bear Case
- Sports expansion has a qualification. CME's 2026-09-07 notice scheduled an end to additional sports and cultural event-swap expiries effective 2026-09-11, pending regulatory review. The notice concerns event swaps; it does not establish cancellation of the separately announced NHL index futures. CME operational notice
- Launch permission remains conditional. The factor announcement dated 2026-08-27 and NHL announcement dated 2026-08-11 retain regulatory-review qualifications. Failure to begin trading on 2026-09-21 or 2026-09-28, respectively, would contradict the dated execution case. Factor announcement, NHL announcement
- Silver adoption remains unmeasured. The 2026-09-07 operational notice scheduled continuous silver trading for 2026-09-11. That date has elapsed, but the notice supplies no subsequent trading results; adoption cannot be inferred from the scheduled start. CME operational notice
Setup & Price Structure
The supplied split/dividend-adjusted series records a 2026-09-11 close of $275.54, a three-month price increase of 2.7%, and a close 12.7% below its $315.74 trailing annual high. Its 14-period relative strength index (RSI) was 52.5. These measured observations do not establish an accelerating breakout.
The $272 weekly-close condition remains the research threshold published on 2026-08-30; it is not presented as a newly measured support shelf. A current moving-average value is missing, so the earlier moving-average reclaim cannot be treated as current evidence.
For crowding, the observable evidence is limited to price momentum and analyst coverage: RSI was 52.5 on 2026-09-11, and TD Cowen's 2026-09-03 target was unchanged at $292. Neither identifies investor concentration, and the available evidence does not support a retail-crowding claim. Benzinga analyst history
Catalyst Calendar (next 30 days)
- 2026-09-21 — E-mini Equity Factor futures. CME's 2026-08-27 announcement specifies this launch date, pending regulatory review. Actual trading would satisfy the first named execution milestone. CME announcement
- 2026-09-28 — NHL index futures. The 2026-08-11 announcement schedules contracts linked to National Hockey League performance statistics, pending regulatory review. Listing and recorded trading would resolve whether the sports-index timetable was met. CME announcement
- 2026-10-05 — Compute and wind contracts. CME's 2026-09-07 notice specifies this trade date for both, pending regulatory review. Wind now has a dated listing milestone; actual trading would establish delivery. CME operational notice
What Would Change Our Mind
Failure to convert the announced calendar into recorded trading would break the execution thesis: factor contracts absent on 2026-09-21, NHL contracts absent on 2026-09-28, or compute contracts absent on 2026-10-05. Those are the company-dated milestones cited above. Independently, a weekly close below $272 would breach the price condition retained from the 2026-08-30 research note.
Meeting the listing dates would resolve execution only. Subsequent contract-level volume and open interest would be needed to assess adoption; the 2026-09-02 August volume release predates these launches and cannot answer that question. CME volume release
Correlation Notes
This is a single-company product-execution thesis; no measured peer-price correlation accompanies the 2026-09-11 price observations. CME's August 2026 release shows interest-rate ADV of 16.7 million contracts versus cryptocurrency ADV of 175,000 contracts. Inferring dependence on cryptocurrency enthusiasm from the new-product headlines would outrun that operating evidence. Contract counts also do not establish revenue contribution, because the release does not provide matching product-level revenue. CME volume release
Notes
- Trailing dividend of $11.35/share includes the January variable payout; the recurring quarterly rate is $1.30, record 2026-09-09, payable 2026-09-25.
- CME publishes ADV monthly in the first business days of the following month, so volume evidence arrives at higher frequency than quarterly earnings.
- New contracts reach the market via CFTC self-certification (Reg 40.2) or voluntary review (Reg 40.3); the 40.3 path runs up to 45 days, extendable to 90.
- Every launch date announced in August 2026 carries explicit 'pending regulatory review' language in CME's own releases; announced dates are not confirmed listings.
- Revenue is levered to volatility across rates, energy and equity index; a quiet macro tape compresses ADV independent of any product news.
Related · shared themes
HPE
Hewlett Packard Enterprise Company
Hewlett Packard Enterprise's AI and networking earnings transition supports a repricing thesis that requires intact growth guidance and the first weekly close above $54.44 after the 2026-09-30 Investor Day. A weekly close below $50 invalidates the price thesis.
NTAP
NetApp, Inc.
NetApp's AI storage recovery requires delivery of September guidance before a weekly close below $164 breaks the thesis. Fiscal-Q2 revenue of at least $2.025 billion and non-GAAP gross margin of at least 67.0%, with the annual revenue outlook issued on 2026-09-02 maintained, would confirm the case.
XMTR
Xometry, Inc.
Xometry's AI manufacturing thesis requires enterprise adoption to deliver its August 4 guidance before a weekly close below $85. Third-quarter revenue of at least $234 million and adjusted EBITDA of at least $16 million, with the 33–34% full-year revenue-growth outlook maintained, would confirm the case.
DELL
Dell Technologies Inc.
Dell Technologies’ AI-server thesis requires roughly $19 billion of next-quarter revenue and infrastructure operating margin of at least 15.0%. The next quarterly results settle that case; September 21, 2026 index inclusion does not resolve the delivery or margin test.
See also · stocks to watch